Skip to content

Investor Relations

Corporate Profile

Emerald Health Therapeutics, Inc. (TSXV: EMH; OTCQX: EMHTF) is committed to creating new consumer experiences with distinct recreational, medical and wellness-oriented cannabis products, with an emphasis on science-based innovation and product excellence.

Investor Resources

Nov 24, 2020

Upcoming Events

No scheduled events at this time.

Stock Information

OPERATING ASSETS

Verdélite, Emerald’s wholly-owned 88,000 square feet indoor grow facility in Saint-Eustache, QC, is a Licensed Producer and has a Standard Processing license, allowing it to not only cultivate and sell cannabis flowers but package, extract, manufacture, synthesize, test and sell next-generation cannabis products. Verdélite is now licensed to sell and distribute packaged, branded dried cannabis products directly to provincial/territorial wholesalers and authorized private retailers. 

Emerald’s Richmond operation has been designed for health and wellness-oriented organic cannabis cultivation and consists of a 78,000 sq. ft. purpose-built greenhouse facility. The facility received its organic certification and is now in full production while a second 78,000 sq. ft greenhouse is under construction. The organically grown products produced at this facility will play an integral role in the expansion of Emerald’s product line. They will be particularly focused on serving adult-use and medical consumers seeking health and wellness benefits.

Victoria, Emerald’s wholly-owned 10,000 square foot facility in Victoria, BC, includes a 2000 square foot indoor grow and a 6000 square foot packaging and extraction operation. Victoria is Emerald’s Medicinal Cannabis hub, where customer relations, packaging and distribution take place. Victoria’s R&D lab is focused on plant genetics, breeding and next generation cannabis products development.

Avalite, Emerald’s wholly-owned analytical testing laboratory, is a Licensed Dealer and authorized to import and export cannabis and cannabis oils for R&D, prepare any manipulation, formulation, dosage form, strength or package size of cannabis, including mixtures with other additives, controlled substances, and non-controlled substances – expanding possible research and product innovation opportunities.

Emerald Health Naturals, Emerald’s 51/49 joint venture with Emerald Health Bioceuticals has exclusive Canadian distribution rights of the award-winning Endo product line (PhytoCann® Complex) of non-cannabis endocannabinoid-supporting products that can be sold through natural health product channels. The unique branding opportunity introduce consumers to the benefits of endocannabinoid-supporting products with the Emerald name.

STRATEGIC PARTNERSHIPS

Emerald entered into a multi-year agreement with Valens GroWorks Corp. to contract cannabis extraction and white-label product development services. Under the Agreement, Emerald will supply Valens with a minimum of 10,000 kg of cannabis and hemp biomass annually for processing into premium quality resins and distillates using Valens’ extraction and processing methods. Valens will also provide white label services including formulation, mixing and filling for product formats such as vaporizers, softgels and tinctures.

Emerald Health Biotechnology Espana is a cannabis-industry-leading research organization which Emerald has contracted to elucidate the mechanism of action of proprietary formulations and dosage forms for product development. This collaboration can strengthen Emerald’s intellectual property portfolio and assist in establishing Emerald as a leader in the development of proprietary cannabis products for medical-use and improved adult-use products with more precise and consistent delivery and dosage.

Rebecca Wong

Vice President, Quality and Regulatory Affairs

Ms. Wong has more than 25 years of managerial experience in quality assurance and quality control spanning research, preclinical, clinical, and commercial phases for pharmaceuticals, combination products, biologicals and medical devices. Before joining Emerald, she was the Executive Director of Quality Assurance at Novelion Therapeutics (formerly QLT Inc.), where she was the head of quality assurance, validation, compliance auditing, document management, and GxP training departments. Ms. Wong previously worked for life science companies including MDS Nordion, Cangene Corporation, and Biomira Inc. Specializing in microbiology, she earned a BSc from the University of Alberta.

Jenn Hepburn

Chief Financial Officer

Ms. Hepburn has over a decade of experience in accounting and finance and is an experienced manager of privately and publicly traded manufacturing and mining businesses operating in Canada and the USA. Prior to joining Emerald, Ms. Hepburn was the Director of Finance and Administration at bioLytical Laboratories Inc., a medical diagnostics manufacturer. Before that, she held controller positions at junior gold and silver mining companies Northern Vertex Mining Corp., Kootenay Silver Inc. and Theia Resources Ltd. Ms. Hepburn earned a BBA from Simon Fraser University and her certification from the Certified Management Accountants of British Columbia.

RIAZ BANDALI

President & Chief Executive Officer

Mr. Bandali’s expertise in global operations, strategy development, driving innovation, M&A, and investment management has been developed over a 25-year career in the life sciences sector spanning contract clinical and research services, analytical instrumentation, lab services and venture capital.

He holds an Advanced Management Program Degree from Harvard Business School, a Master of Business Administration from McGill University, and a Bachelor of Science from the University of British Columbia. He is an innovative business leader who has built strategic and operating plans that have resulted in rapid growth and significant profitability enhancement. He has managed businesses and operations with a global footprint and has led teams of over 900 people.

Mr. Bandali’s previous experience includes serving as President, Early Phase Clinical Services and Translational Science, Syneos Health; President, Early Stage Development, as well as Chief Innovation Officer, inVentiv Health Clinical; Senior Vice President, Strategy and Business Development, AB Sciex and Molecular Devices (part of Danaher Corporation); Senior Vice President, Strategy, Legal and Corporate Development, MDS Analytical Technologies; and Vice President and General Manager, Global Early Stage Development, MDS Pharma Services. He was also Venture Partner and Vice President at MDS Capital and has served on the boards of private and public companies.